The session focused on “Biomanufacturing of Enzymes,” a critical domain under the BioE3 Policy.
India has reached to nearly 6,000 bio-startups from 50 in the past 10 years
Support for biologics manufacturability and Industry 4.0 initiatives
Support for bioprocess, cell and gene therapy, and industry 4.0 initiatives
Bangladesh, Indonesia, Pakistan, Serbia and Vietnam to receive mRNA technology from the technology transfer hub
ExellenS applies optimized facility designs, equipment, and processes across all sites to ensure equivalency and speed
Several technologies for hemoglobinopathies are being transferred to commercial partners
Amgen has invested over $40 billion in manufacturing and research and development in US since 2017
Subscribe To Our Newsletter & Stay Updated